Cell Morphometry Guides Nanoparticle-Mediated Chemoradiotherapy Against Brain Cancers
A Benoit*, A Hubbard, Y Walter, O Salas, E Jank, A Ekpenyong, Creighton University, Omaha, NE
Presentations
MO-F-BRC-3 (Monday, 7/11/2022) 1:45 PM - 2:45 PM [Eastern Time (GMT-4)]
Ballroom C
Purpose: Glioblastoma is the most common form of brain cancer affecting over 12,000 people per year in the United States. It is commonly treated with a combination of chemotherapy and radiotherapy. The purpose of this study is to optimize nanoparticle-mediated chemoradiotherapy against brain cancers using fluorescence imaging.
Methods: Glioblastoma cell lines T98G and U87 were irradiated using a cell irradiator (Faxitron CellRad) and treated with quantum dots and the chemotherapeutic drug, Temozolomide (TMZ). Fluorescence images of a variety of combinations are taken at the start of treatment and then 24 hours after treatment. The damage to the glioblastoma cells is detected and quantified by the morphometric changes shown in the fluorescent imaging. The dye Hoechst is used to stain the nucleic acids, highlighting the DNA material in the nucleus. While the dye, Calcein, stains the cytoplasm, which allows for a comparison between nucleus and cytoplasm.
Results: The fluorescence images, even without further morphometry, reveal that the nanoparticle-mediated chemoradiotherapeutic interventions disrupt the structure of DNA, harming rapidly dividing cells of the tumor. Our morphometric analysis using parameters such as lacunarity, circularity, mitotic cell count, and nuclear-to-cytoplasm ratio quantify the damage caused by cell exposure to chemotherapy, radiation, and exposure to nanoparticles.
Conclusion: Our preliminary results suggest that fluorescence imaging enables robust and very early quantitative assessment of possible treatment efficacy for nanoparticle mediated chemoradiotherapy against brain cancers.
Keywords
Not Applicable / None Entered.
Taxonomy
TH- Radiobiology(RBio)/Biology(Bio): Bio- tissue and microenvironment
Contact Email